Method, system, and computer program product for the processing of self-monitoring blood glucose(SMBG)data to enhance diabetic self-management
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G06F-019/00
A61B-005/00
A61B-005/05
출원번호
US-0524094
(2003-08-08)
등록번호
US-8538703
(2013-09-17)
국제출원번호
PCT/US03/25053
(2003-08-08)
§371/§102 date
20050209
(20050209)
국제공개번호
WO2004/015539
(2004-02-19)
발명자
/ 주소
Kovatchev, Boris P.
Cox, Daniel J.
출원인 / 주소
University of Virginia Patent Foundation
대리인 / 주소
Novak Druce Connolly Bove + Quigg LLP
인용정보
피인용 횟수 :
4인용 특허 :
37
초록▼
A method, system, and computer program product related to the maintenance of optimal control of diabetes, and is directed to predicting the long-term exposure to hyperglycemia, and the long-term and short-term risks of severe or moderate hypoglycemia in diabetics, based on blood blucose readings col
A method, system, and computer program product related to the maintenance of optimal control of diabetes, and is directed to predicting the long-term exposure to hyperglycemia, and the long-term and short-term risks of severe or moderate hypoglycemia in diabetics, based on blood blucose readings collected by a self-monitoring blood glucose device. The method, system, and computer program product pertain directly to the enhancement of existing home blood glucose monitoring devices, by introducing an intelligent data interpretation component capable of predicting both HbA1c and periods of increased risk of hypoglycemia, and to the enhancement of emerging continuous monitoring devices by the same features. With these predictions the diabetic can take steps to prevent the adverse consequences associated with hyperglycemia and hypoglycemia.
대표청구항▼
1. A system for evaluating the HbA1c of a patient based on blood glucose (BG) data collected over a first predetermined duration, said system comprising: a database component operative to maintain a database identifying said BG data; anda processor programmed to: pre-process the collected BG data to
1. A system for evaluating the HbA1c of a patient based on blood glucose (BG) data collected over a first predetermined duration, said system comprising: a database component operative to maintain a database identifying said BG data; anda processor programmed to: pre-process the collected BG data to convert the collected BG data into derived BG data derived from said collected BG data, estimate HbA1c by applying at least one predetermined formula to said derived BG data,validate the estimate via sample selection criteria; andoutput the estimate to a user. 2. The system of claim 1, wherein said first predetermined duration is about 60 days. 3. The system of claim 1, wherein said first predetermined duration ranges from about 45 days to about 75 days. 4. The system of claim 1, wherein said first predetermined duration ranges from about 45 days to about 90 days. 5. The system of claim 1, wherein the preprocessing of the data comprises: conversion of plasma to whole blood BG mg/dl;conversion of BG measured in mg/dl to units of mmol/l; andcomputing Low Blood Glucose Index (RLO1) and High Blood Glucose Index (RHI1). 6. The system of claim 1, wherein the preprocessing of the data comprises: conversion of plasma to whole blood BG mg/dl via BG=PLASBG (mg/dl) /1.12;conversion of BG measured in mg/dl to units of mmol/l) via BGMM=BG/18; andcomputing Low Blood Glucose Index (RLO1) and High Blood Glucose Index (RHI1) using a predetermined mathematical formula defined as: Scale=[ln(BG)]1.0845−5.381, wherein BG is measured in units of mg/dl,Risk1=22.765(Scale)2, whereinRiskLO=Risk1 if (BG is less than about 112.5) and therefore risk of LBGI exists, otherwise RiskLO=0, andRiskHI=Risk1 if (BG is greater than about 112.5) and therefore risk of HBGI exists, otherwise RiskHI=0,BGMM1=average of BGMM per patient,RLO1=average of RiskLO per patient,RHI1=average of RiskHI per patient,L06=average of RiskLO computed only for readings during the night, otherwise missing if there are no readings at night,N06, N12, N24 are percentage of SMBG readings in time intervals,NC1=total number of SMBG readings in the first predetermined duration; andNDAYS=number of days with SMBG readings in the first predetermined duration. 7. The system of claim 6, wherein the N06, N12, N24 are percentage of SMBG readings in time intervals of about 0-6:59 hour time period; about 7-12:59 hour time period, and about 18-23:59 hour time period, respectively. 8. The system of claim 6, comprising assigning a group depending on the patient's computed High BG Index using a predetermined mathematical formula defined as: if (RHI1 is ≦about 5.25 or if RHI1 is ≧about 16) then the assigned group=0,if (RHI1 is >about 5.25 and if RHI1 is about 26) then EST2=E0−1.5*RLO1, andif ((RLO1/RHI1) is ≦about 0.25 and L06 is >about 1.3) then EST2=EST2-0.08. 11. The system of claim 10 for estimating the HbA1c of a patient based on BG data collected over the first predetermined duration, wherein said estimating HbA1c comprises : a) HbA1c=the EST2 defined by claim 8 or as corrected by claim 10 orb) HbA1c=0.809098*BGMM1+0.064540*RLO1−0.151673*RHI1+1.873325, wherein BGMM1 is the average BG (mmol/l) of claim 6,RLO1 is the Low BG Index of claim 6,RHI1 is the High BG Index of claim 6; orc) HbA1c=0.682742*HBA0+0.054377*RHI1+1.553277, wherein HBA0 is a previous reference HbA1c reading taken about a second predetermined period prior to the estimate, wherein RHI1=is the High BG Index of claim 6; ord) HbA1c=0.41046*BGMM+4.0775wherein BGMM1is the average BG (mmol/l) of claim 6. 12. The system of claim 11, wherein said second predetermined duration is about three months. 13. The system of claim 11, wherein said second predetermined duration ranges from about 2.5 months to about 3.5 months. 14. The system of claim 11, wherein said second predetermined duration ranges from about 2.5 months to six months. 15. The system of claim 11, wherein the validation of the HbA1c estimate using sample selection criteria of HbA1c estimate only if the first predetermined duration sample meets at least one of the following four criteria: a) a test frequency criterion wherein if the first predetermined duration sample contains an average of at least about 1.5 to about 2.5 tests per day;b) an alternative test frequency criterion only if the predetermined duration sample contains at least a third predetermined sample period with readings with an average frequency of about 1.8 readings/day;c) a randomness of data criterion-1 wherein the HbA1c estimate is validated or displayed only if the ratio (RLO1/RHI1>=about 0.005), whereinRLO1 is the Low BG Index of claim 6,RHI1 is the High BG Index of claim 6; ord) a randomness of data criterion-2 wherein HbA1c estimate is validated or displayed only if the ratio (NO6>=about 3%), whereinN06 is the percentage of readings during the night of claim 6. 16. The system of claim 15, wherein said third predetermined duration is at least 35 days. 17. The system of claim 15, wherein said third predetermined duration ranges from about 35 days to about 40 days. 18. The system of claim 15, wherein said third predetermined duration ranges from about 35 days to about as long as the first predetermined duration. 19. The system of claim 11, wherein the validation of the HbA1c estimate using sample selection criteria of HbA1c estimate only if the first predetermined duration sample meets at least one of the following four criteria: a) a test frequency criterion wherein if the first predetermined duration sample contains an average of at least about 1.5; andb) a randomness of data criterion-1 wherein the HbA1c estimate is validated or displayed only if the ratio (RLO1/RHI1>=about 0.005), whereinRLO1 is the Low BG Index of claim 6RHI1 is the High BG Index of claim 6; orc) a randomness of data criterion-2 wherein HbA1c estimate is validated or displayed only if the ratio (NO6>=about 3%), whereinN06 is the percentage of readings during the night of claim 6. 20. The system of claim 19, wherein said third predetermined duration is at least about 35 days. 21. A system for evaluating the HbA1c of a patient based on blood glucose (BG) data collected over a first predetermined duration, said system comprising: a BG acquisition mechanism, said acquisition mechanism configured to acquire BG data from the patient;a database component operative to maintain a database identifying said BG data; anda processor programmed to: pre-process the acquired BG data to convert the acquired BG data into derived BG data derived from said acquired BG data;estimate HbA1c by applying at least one predetermined formula to said derived BG data;validate the estimate via sample selection criteria; andoutput the estimate to a user. 22. The system of claim 21, wherein said first predetermined duration is about 60 days. 23. The system of claim 21, wherein said first predetermined duration ranges from about 45 days to about 75 days. 24. The system of claim 21, wherein said first predetermined duration ranges from about 45 days to about 90 days. 25. The system of claim 21, wherein the pre-processing of the data comprises: conversion of plasma data to whole blood BG mg/dl;conversion of BG measured in mg/dl to units of mmol/l; andcomputing Low Blood Glucose Index (RLO1) and High Blood Glucose Index (RHI1). 26. The system of claim 21, wherein the preprocessing of the data comprises: conversion of plasma data to whole blood BG mg/dl via BG=PLASBG (mg/dl) /1.12;conversion of BG measured in mg/dl to units of mmol/l) via BGMM=BG/18; andcomputing Low Blood Glucose Index (RLO1) and High Blood Glucose Index (RHI1) using a predetermined mathematical formula defined as: Scale=[ln(BG)]1.0845−5.381, wherein BG is measured in units of mg/dl,Risk1=22.765(Scale)2, whereinRiskLO=Risk1 if (BG is less than about 112.5) and therefore risk of LBGI exists, otherwise RiskLO=0, andRiskHI=Risk1 if (BG is greater than about 112.5) and therefore risk of HBGI exists, otherwise RiskHI=0,BGMM1=average of BGMM per patient,RLO1=average of RiskLO per patient,RHI1=average of RiskHI per patient,L06=average of RiskLO computed only for readings during the night, otherwise missing if there are no readings at night,N06, N12, N24 are percentage of SMBG readings in time intervals,NC1=total number of SMBG readings in the first predetermined duration; andNDAYS=number of days with SMBG readings in the first predetermined duration. 27. The system of claim 26, wherein the N06, N12, N24 are percentage of SMBG readings in time intervals of about 0-6:59 hour time period; about 7-12:59 hour time period, and about 18-23:59 hour time period, respectively. 28. The system of claim 26, comprising assigning a group depending on the patient's computed High BG Index using a predetermined mathematical formula defined as: if (RHI1 is ≦about 5.25 or if RHI1 is ≧about 16) then the assigned group=0,if (RHI1 is >about 5.25 and if RHI1 is about 26) then EST2=E0−1.5*RLO1, andif ((RLO1/RHI1) is ≦about 0.25 and L06 is >about 1.3) then EST2=EST2−0.08. 31. The system of claim 30 for estimating the HbA1c of a patient based on BG data collected over the first predetermined duration, said system comprising: said estimating HbA1c using said at least one of four predetermined mathematical formulas defined as:a) HbA1c=the EST2 defined by claim 28 or as corrected by claim 30 orb) HbA1c=0.809098*BGMM1+0.064540*RLO1-0.151673*RHI1+1.873325, wherein BGMM1is the average BG (mmol/l) of claim 26,RLO1 is the Low BG Index of claim 26,RHI1 is the High BG Index of claim 26; orc) HbA1c=0.682742*HBA0+0.054377*RHI1+1.553277, wherein HBA0 is a previous reference HbA1c reading taken about a second predetermined period prior to the estimate, wherein RHI1=is the High BG Index of claim 26; ord) HbA1c=0.41046*BGMM+4.0775wherein BGMM1is the average BG (mmol/l) of claim 26. 32. The system of claim 31, wherein said second predetermined duration is about three months. 33. The system of claim 31, wherein said second predetermined duration ranges from about 2.5 months to about 3.5 months. 34. The system of claim 31, wherein said second predetermined duration ranges from about 2.5 months to six months. 35. The system of claim 31, wherein the validation of the HbA1c estimate using sample selection criteria of HbA1c estimate only if the first predetermined duration sample meets at least one of the following four criteria: a) a test frequency criterion wherein if the first predetermined duration sample contains an average of at least about 1.5 to about 2.5 tests per day;b) an alternative test frequency criterion only if the predetermined duration sample contains at least a third predetermined sample period with readings with an average frequency of about 1.8 readings/day;c) a randomness of data criterion-1 wherein the HbA1c estimate is validated or displayed only if the ratio (RLO1/RHI1>=about 0.005), whereinRLO1 is the Low BG Index of claim 26,RHI1 is the High BG Index of claim 26; ord) a randomness of data criterion-2 wherein HbA1c estimate is validated or displayed only if the ratio (NO6>=about 3%), whereinN06 is the percentage of readings during the night of claim 26. 36. The system of claim 35, wherein said third predetermined duration is at least 35 days. 37. The system of claim 35, wherein said third predetermined duration ranges from about 35 days to about 40 days. 38. The system of claim 35, wherein said third predetermined duration ranges from about 35 days to about as long as the first predetermined duration. 39. The system of claim 31, wherein the validation of the HbA1c estimate using sample selection criteria of HbA1c estimate only if the first predetermined duration sample meets at least one of the following four criteria: a) a test frequency criterion wherein if the first predetermined duration sample contains an average of at least about 1.5; andb) a randomness of data criterion-1 wherein the HbA1c estimate is validated or displayed only if the ratio (RLO1/RHI1>=about 0.005), whereinRLO1 is the Low BG Index of claim 26RHI1 is the High BG Index of claim 26; orc) a randomness of data criterion-2 wherein HbA1c estimate is validated or displayed only if the ratio (NO6>=about 3%), whereinN06 is the percentage of readings during the night of claim 26. 40. The system of claim 39, wherein said third predetermined duration is at least about 35 days. 41. A computer program product comprising a tangible computer readable medium having computer program logic for enabling at least one processor in a computer system to evaluate the HbA1c of a patient based on blood glucose (BG) data collected over a first predetermined duration, said computer program logic comprising: pre-processing of the collected BG data to convert the collected BG data into derived BG data derived from said collected BG data, estimating HbA1c by applying at least one predetermined formula to said derived BG data, andvalidation of the estimate via sample selection criteria; andoutputting the estimate to a user. 42. A system for evaluating the HbA1c of a patient based on blood glucose (BG) data collected over a first predetermined duration, said system comprising: a database component operative to maintain a database identifying said BG data; anda processor programmed to: pre-process the collected BG data to convert the collected BG data into derived BG data derived from said collected BG data, validate a sample of the collected BG data via sample selection criteria, andestimate HbA1c from said derived BG data if the sample is valid; andoutput the estimate to a user. 43. The system of claim 42, wherein said first predetermined duration is about 60 days. 44. The system of claim 42, wherein said first predetermined duration ranges from about 45 days to about 75 days. 45. The system of claim 42, wherein said first predetermined duration ranges from about 45 days to about 90 days. 46. The system of claim 42, wherein the preprocessing of the data comprises: conversion of plasma to whole blood BG mg/dl;conversion of BG measured in mg/dl to units of mmol/l; andcomputing Low Blood Glucose Index (RLO1) and High Blood Glucose Index (RHI1). 47. The system of claim 42, wherein the preprocessing of the data comprises: conversion of plasma to whole blood BG mg/dl via BG=PLASBG (mg/dl) /1.12;conversion of BG measured in mg/dl to units of mmol/l via BGMM=BG/18; andcomputing Low Blood Glucose Index (RLO1) and High Blood Glucose Index (RHI1) using a predetermined mathematical formula defined as:Scale=[ln(BG)]1.0845−5.381, wherein BG is measured in units of mg/dl,Risk1=22.765(Scale)2, whereinRiskLO=Risk1 if (BG is less than about 112.5) and therefore risk of LBGI exists, otherwise RiskLO=0, andRiskHI=Risk1 if (BG is greater than about 112.5) and therefore risk of HBGI exists, otherwise RiskHI=0,BGMM1=average of BGMM per patient,RLO1=average of RiskLO per patient,RHI1=average of RiskHI per patient,L06=average of RiskLO computed only for readings during the night, otherwise missing if there are no readings at night,N06, N12, N24 are percentage of SMBG readings in time intervals,NC1=total number of SMBG readings in the first predetermined duration; andNDAYS=number of days with SMBG readings in the first predetermined duration. 48. The system of claim 47, wherein the N06, N12, N24 are percentage of SMBG readings in time intervals of about 0-6:59 hour time period; about 7-12:59 hour time period, and about 18-23:59 hour time period, respectively. 49. The system of claim 47, comprising assigning a group depending on the patient's computed High BG Index using a predetermined mathematical formula defined as: if (RHI1 is ≦about 5.25 or if RHI1 is ≧about 16) then the assigned group=0,if (RHI1 is >about 5.25 and if RHI1 is about 26) then EST2=E0−1.5*RLO1, andif ((RLO1/RHI1) is ≦about 0.25 and L06 is >about 1.3) then EST2=EST2-0.08. 52. The system of claim 51 for estimating the HbA1c of a patient based on BG data collected over the first predetermined duration, said system comprising: estimating HbA1c using at least one of four predetermined mathematical formulas defined as:a) HbA1c=the EST2 defined by claim 49 or as corrected by claim 51 orb) HbA1c=0.809098*BGMM1+0.064540*RLO1-0.151673*RHI1+1.873325, wherein BGMM1is the average BG (mmol/l) of claim 47,RLO1 is the Low BG Index of claim 47,RHI1 is the High BG Index of claim 47; orc) HbA1c=0.682742*HBA0+0.054377*RHI1+1.553277, wherein HBA0 is a previous reference HbA1c reading taken about a second predetermined period prior to the estimate, wherein RHI1=is the High BG Index of claim 47; ord) HbA1c=0.41046*BGMM+4.0775wherein BGMM1is the average BG (mmol/l) of claim 47. 53. The system of claim 52, wherein said second predetermined duration is about three months. 54. The system of claim 52, wherein said second predetermined duration ranges from about 2.5 months to about 3.5 months. 55. The system of claim 52, wherein said second predetermined duration ranges from about 2.5 months to six months. 56. The system of claim 52, wherein the validation of the sample using sample selection criteria of HbA1c estimate only if the first predetermined duration sample meets at least one of the following four criteria: a) a test frequency criterion wherein if the first predetermined duration sample contains an average of at least about 1.5to about 2.5 tests per day;b) an alternative test frequency criterion only if the predetermined duration sample contains at least a third predetermined sample period with readings with an average frequency of about 1.8 readings/day;c) a randomness of data criterion-1 wherein the HbA1c estimate is validated or displayed only if the ratio (RLO1/RHI1>=about 0.005), whereinRLO1 is the Low BG Index of claim 47,RHI1 is the High BG Index of claim 47; ord) a randomness of data criterion-2 wherein HbA1c estimate is validated or displayed only if the ratio (NO6>=about 3%), whereinN06 is the percentage of readings during the night of claim 47. 57. The system of claim 56, wherein said third predetermined duration is at least 35 days. 58. The system of claim 56, wherein said third predetermined duration ranges from about 35 days to about 40 days. 59. The system of claim 56, wherein said third predetermined duration ranges from about 35 days to about as long as the first predetermined duration. 60. The system of claim 52, wherein the validation of the sample using sample selection criteria of HbA1c estimate only if the first predetermined duration sample meets at least one of the following four criteria: a) a test frequency criterion wherein if the first predetermined duration sample contains an average of at least about 1.5; andb) a randomness of data criterion-1 wherein the HbA1c estimate is validated or displayed only if the ratio (RLO1/RHI1>=about 0.005), whereinRLO1 is the Low BG Index of claim 47RHI1 is the High BG Index of claim 47; orc) a randomness of data criterion-2 wherein HbA1c estimate is validated or displayed only if the ratio (NO6>=about 3%), whereinN06 is the percentage of readings during the night of claim 47. 61. The system of claim 60, wherein said third predetermined duration is at least about 35 days. 62. A system for evaluating the HbA1c of a patient based on blood glucose (BG) data collected over a first predetermined duration, said system comprising: a BG acquisition mechanism, said acquisition mechanism configured to acquire BG data from the patient;a database component operative to maintain a database identifying said BG data; anda processor programmed to: pre-process the acquired BG data to convert the acquired BG data into derived BG data derived from said acquired BG data;validate a sample of the acquired BG data via sample selection criteria;estimate HbA1c from said derived BG data if the sample is valid; andoutput the HbA1c estimate to a user. 63. The system of claim 62, wherein said first predetermined duration is about 60 days. 64. The system of claim 62, wherein said first predetermined duration ranges from about 45 days to about 75 days. 65. The system of claim 62, wherein said first predetermined duration ranges from about 45 days to about 90 days. 66. The system of claim 62, wherein the preprocessing of the data comprises: conversion of plasma to whole blood BG mg/dl;conversion of BG measured in mg/dl to units of mmol/l; andcomputing Low Blood Glucose Index (RLO1) and High Blood Glucose Index (RHI1). 67. The system of claim 62, wherein the pre-processing of the data comprises: conversion of plasma to whole blood BG mg/dl via BG=PLASBG (mg/dl) /1.12;conversion of BG measured in mg/dl to units of mmol/l) via BGMM=BG/18; andcomputing Low Blood Glucose Index (RLO1) and High Blood Glucose Index (RHI1) using a predetermined mathematical formula defined as: Scale=[ln(BG)]1.0845−5.381, wherein BG is measured in units of mg/dl,Risk1=22.765(Scale)2, whereinRiskLO=Risk1 if (BG is less than about 112.5) and therefore risk of LBGI exists, otherwise RiskLO=0, andRiskHI=Risk1 if (BG is greater than about 112.5) and therefore risk of HBGI exists, otherwise RiskHI=0,BGMM1=average of BGMM per patient,RLO1=average of RiskLO per patient,RHI1=average of RiskHI per patient,L06=average of RiskLO computed only for readings during the night, otherwise missing if there are no readings at night,N06, N12, N24 are percentage of SMBG readings in time intervals,NC1=total number of SMBG readings in the first predetermined duration; andNDAYS=number of days with SMBG readings in the first predetermined duration. 68. The system of claim 67, wherein the N06, N12, N24 are percentage of SMBG readings in time intervals of about 0-6:59 hour time period; about 7-12:59 hour time period, and about 18-23:59 hour time period, respectively. 69. The system of claim 67, comprising assigning a group depending on the patient's computed High BG Index using a predetermined mathematical formula defined as: if (RHI1 is ≦about 5.25 or if RHI1 is ≧about 16) then the assigned group=0,if (RHI1 is >about 5.25 and if RHI1 is about 26) then EST2=E0−1.5*RLO1, andif ((RLO1/RHI1) is ≦about 0.25 and L06 is >about 1.3) then EST2=EST2-0.08. 72. The system of claim 71 for estimating the HbA1c of a patient based on BG data collected over the first predetermined duration, said system comprising: estimating HbA1c using at least one of four predetermined mathematical formulas defined as:a) HbA1c=the EST2 defined by claim 69 or as corrected by claim 71 orb) HbA1c=0.809098*BGMM1+0.064540*RLO1-0.151673*RHI1+1.873325, wherein BGMM1is the average BG (mmol/l) of claim 67,RLO1 is the Low BG Index of claim 67,RHI1 is the High BG Index of claim 67; orc) HbA1c=0.682742*HBA0+0.054377*RHI1+1.553277, wherein HBA0is a previous reference HbA1c reading taken about a second predetermined period prior to the estimate, wherein RHI1=is the High BG Index of claim 67; ord) HbA1c=0.41046*BGMM+4.0775wherein BGMM1is the average BG (mmol/l) of claim 67. 73. The system of claim 72, wherein said second predetermined duration is about three months. 74. The system of claim 72, wherein said second predetermined duration ranges from about 2.5 months to about 3.5 months. 75. The system of claim 72, wherein said second predetermined duration ranges from about 2.5 months to six months. 76. The system of claim 72, wherein the validation of the sample using sample selection criteria of HbA1c estimate only if the first predetermined duration sample meets at least one of the following four criteria: a) a test frequency criterion wherein if the first predetermined duration sample contains an average of at least about 1.5to about 2.5 tests per day;b) an alternative test frequency criterion only if the predetermined duration sample contains at least a third predetermined sample period with readings with an average frequency of about 1.8 readings/day;c) a randomness of data criterion-1 wherein the HbA1c estimate is validated or displayed only if the ratio (RLO1/RHI1>=about 0.005), whereinRLO1 is the Low BG Index of claim 67,RHI1 is the High BG Index of claim 67; ord) a randomness of data criterion-2 wherein HbA1c estimate is validated or displayed only if the ratio (NO6>=about 3%), whereinN06 is the percentage of readings during the night of claim 67. 77. The system of claim 76, wherein said third predetermined duration is at least 35 days. 78. The system of claim 76, wherein said third predetermined duration ranges from about 35 days to about 40 days. 79. The system of claim 76, wherein said third predetermined duration ranges from about 35 days to about as long as the first predetermined duration. 80. The system of claim 72, wherein the validation of the sample using sample selection criteria of HbA1c estimate only if the first predetermined duration sample meets at least one of the following four criteria: a) a test frequency criterion wherein if the first predetermined duration sample contains an average of at least about 1.5; andb) a randomness of data criterion-1 wherein the HbA1c estimate is validated or displayed only if the ratio (RLO1/RHI1>=about 0.005), whereinRLO1 is the Low BG Index of claim 67RHI1 is the High BG Index of claim 67; orc) a randomness of data criterion-2 wherein HbA1c estimate is validated or displayed only if the ratio (NO6>=about 3%), whereinN06 is the percentage of readings during the night of claim 67. 81. The system of claim 80, wherein said third predetermined duration is at least about 35 days. 82. A system for evaluating the HbA1c of a patient without the need for prior HbA1c information based on blood glucose (BG) data collected over a first predetermined duration, said system comprising: a database component operative to maintain a database identifying said BG data; anda processor programmed to: pre-process the collected BG data to convert the collected BG data into derived BG data derived from said collected BG data,validate a sample of the collected BG data via sample selection criteria, andestimate HbA1c from said derived BG data if the sample is valid; andoutput the estimate to a user. 83. The system of claim 82, wherein said first predetermined duration is about 60 days. 84. The system of claim 82, wherein said first predetermined duration ranges from about 45 days to about 75 days. 85. The system of claim 82, wherein said first predetermined duration ranges from about 45 days to about 90 days. 86. The system of claim 82, wherein the preprocessing of the data comprises: conversion of plasma data to whole blood BG mg/dl;conversion of BG measured in mg/dl to units of mmol/l; andcomputing Low Blood Glucose Index (RLO1) and High Blood Glucose Index (RHI1). 87. The system of claim 82, wherein the preprocessing of the data comprises: conversion of plasma to whole blood BG mg/dl via BG=PLASBG (mg/dl) /1.12;conversion of BG measured in mg/dl to units of mmol/l via BGMM=BG/18; andcomputing Low Blood Glucose Index (RLO1) and High Blood Glucose Index (RHI1) using a predetermined mathematical formula defined as: Scale=[ln(BG)]1.0845−5.381, wherein BG is measured in units of mg/dl,Risk1=22.765(Scale)2, whereinRiskLO=Risk1 if (BG is less than about 112.5) and therefore risk of LBGI exists, otherwise RiskLO=0, andRiskHI=Risk1 if (BG is greater than about 112.5) and therefore risk of HBGI exists, otherwise RiskHI=0,BGMM1=average of BGMM per patient,RLO1=average of RiskLO per patient,RHI1=average of RiskHI per patient,L06=average of RiskLO computed only for readings during the night, otherwise missing if there are no readings at night,N06, N12, N24 are percentage of SMBG readings in time intervals,NC1=total number of SMBG readings in the first predetermined duration; andNDAYS=number of days with SMBG readings in the first predetermined duration. 88. A system for evaluating the HbA1c of a patient without the need for prior HbA1c information based on blood glucose (BG) data collected over a first predetermined duration, said system comprising: a BG acquisition mechanism, said acquisition mechanism configured to acquire BG data from the patient;a database component operative to maintain a database identifying said BG data; anda processor programmed to: pre-process the collected BG data to convert the collected BG data into derived BG data derived from said collected BG data;validate a sample of the collected BG data via sample selection criteria;estimate HbA1c from said derived BG data if the sample is valid; andoutput the HbA1c estimate to a user. 89. The system of claim 88, wherein said first predetermined duration is about 60 days. 90. The system of claim 88, wherein said first predetermined duration ranges from about 45 days to about 75 days. 91. The system of claim 88, wherein said first predetermined duration ranges from about 45 days to about 90 days. 92. The system of claim 88, wherein the preprocessing of the data comprises: conversion of plasma data to whole blood BG mg/dl;conversion of BG measured in mg/dl to units of mmol/l; andcomputing Low Blood Glucose Index (RLO1) and High Blood Glucose Index (RHI1). 93. The system of claim 88, wherein the preprocessing of the data is defined as: conversion of plasma to whole blood BG mg/dl via BG=PLASBG (mg/dl) /1.12;conversion of BG measured in mg/dl to units of mmol/l via BGMM=BG/18; andcomputing Low Blood Glucose Index (RLO1) and High Blood Glucose Index (RHI1) using a predetermined mathematical formula defined as: Scale=[ln(BG)]1.0845−5.381, wherein BG is measured in units of mg/dl,Risk1=22.765(Scale)2, whereinRiskLO=Risk1 if (BG is less than about 112.5) and therefore risk of LBGI exists, otherwise RiskLO=0, andRiskHI=Risk1 if (BG is greater than about 112.5) and therefore risk of HBGI exists, otherwise RiskHI=0,BGMM1=average of BGMM per patient,RLO1=average of RiskLO per patient,RHI1=average of RiskHI per patient,L06=average of RiskLO computed only for readings during the night, otherwise missing if there are no readings at night,N06, N12, N24 are percentage of SMBG readings in time intervals,NC1=total number of SMBG readings in the first predetermined duration; andNDAYS=number of days with SMBG readings in the first predetermined duration.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (37)
Hirai Kikuo,JPX ; Shinoki Hiroshi,JPX ; Ogawa Masashi,JPX ; Makino Yoshihiko,JPX, Analysis element and method for analyzing glycated hemoglobin content ratio.
Say James ; Tomasco Michael F. ; Heller Adam ; Gal Yoram,ILX ; Aria Behrad ; Heller Ephraim ; Plante Phillip John ; Vreeke Mark S. ; Friedman Keith A. ; Colman Fredric C., Analyte monitoring device and methods of use.
Stanley Theodore H. (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT) Higuchi William I. (Salt Lake City UT) Zhang Jie (Salt Lake City UT), Apparatus and method for noninvasive blood glucose monitoring.
Galen Robert S. ; Burd John F. ; Hoblitzell Talei ; Neyer Gebhard, Apparatus for combined assay for current glucose level and intermediate or long-term glycemic control.
Glikfeld Peretz (San Francisco CA) Cullander Christopher (Berkeley CA) Hinz Robert S. (Mill Valley CA) Guy Richard H. (Daley City CA), Device for iontophoretic non-invasive sampling or delivery of substances.
Kahn Michael G. (St. Louis MO) Huang Dijia (Granger IN) Bussmann Stephen A. (Granger IN) Cousins Steve B. (St. Louis MO) Abrams Charlene A. (St. Louis MO) Beard James C. (University City MO), Diabetes data analysis and interpretation method.
Yamazaki Kazutoshi (Ohtsu JPX) Takechi Masahiro (Nishinomiya JPX) Kawabe Toshiki (Kyoto JPX) Yokoi Masayuki (Kusatsu JPX), Eliminating agent for glycosylated hemoglobin and a test method using the same.
Szuminsky Neil J. (Pittsburgh PA) Jordan Joseph (State College PA) Pottgen Paul A. (Allison Park PA) Talbott Jonathan L. (Freedom PA), Method and apparatus for amperometric diagnostic analysis.
Szuminsky Neil J. (Pittsburgh PA) Jordan Joseph (State College PA) Pottgen Paul A. (Allison Park PA) Talbott Jonathan L. (Freedom PA), Method and apparatus for amperometric diagnostic analysis.
Robinson Mark R. (Albuquerque NM) Ward Kenneth J. (Albuquerque NM) Eaton Robert P. (Albuquerque NM) Haaland David M. (Albuquerque NM), Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biolo.
Kovatchev,Boris P.; Cox,Daniel J., Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data.
Berner Bret ; Chiang Chia-Ming ; Garrison Michael D. ; Jona Janan ; Potts Russell O. ; Tamada Janet A. ; Tierney Michael J., Monitoring of physiological analytes.
Yang Won S. (6-405 ; Donga APT. ; 26 Chang-dong ; Dobong-ku ; Seoul KRX) Kim Yoon O. (865-2 Daerim-dong ; Youngdungpo-ku ; Seoul KRX), Non-invasive method and apparatus for measuring blood glucose concentration.
Evers David C. (Acworth GA) Lindsey A. Darrell (Marrietta GA) Finch Marcus (Atlanta GA) Gorsuch Reynolds G. F. (Yountville CA), Patient monitor and support system.
Berner Bret ; Dunn Timothy C. ; Farinas Kathleen C. ; Garrison Michael D. ; Kurnik Ronald T. ; Lesho Matthew J. ; Potts Russell O. ; Tamada Janet A. ; Tierney Michael J., Signal processing for measurement of physiological analysis.
Renirie Alexis C. M.,NLX ; Houben Richard,NLX ; van Leeuwen Frank,NLX, System and method for continuous monitoring of diabetes-related blood constituents.
Barry David W. ; Underwood Carolyn S. ; McCreedy Bruce J. ; Hadden David D. ; Lucas Jason L., Systems, methods and computer program products for guiding the selection of therapeutic treatment regimens.
Barry David W. ; Underwood Carolyn S. ; McCreedy Bruce J. ; Hadden David D. ; Lucas Jason L., Systems, methods and computer program products for guiding the selection of therapeutic treatment regimens.
Kaya, Lutfi Ilke; Tang, Bangsheng; Yang, Tong; Kehler, Christopher Russell; Zhang, Chi, Generation, ranking, and delivery of actions for entities in a video delivery system.
Kaya, Ilke; Elston, Devin; Tang, Bangsheng; Yao, Jinyu; Su, Heng; Liu, Mingkui; Kolasinski, Jordan, Personalized generation of watch list of shows in a video delivery system.
Davis, Anna Leigh; Belliveau, Scott M.; Bhavaraju, Naresh C.; Bowman, Leif N.; Castillo, Rita M.; Constantin, Alexandra Elena; Draeger, Rian; Dunn, Laura J.; Gable, Gary Brian; Garcia, Arturo; Hall, Thomas; Hampapuram, Hari; Hannemann, Christopher Robert; Harley-Trochimczyk, Anna Claire; Heintzman, Nathaniel David; Jackson, Andrea J.; Jepson, Lauren Hruby; Kamath, Apurv Ullas; Koehler, Katherine Yerre; Mandapaka, Aditya Sagar; Marsh, Samuel Jere; Morris, Gary A.; Pai, Subrai Girish; Pal, Andrew Attila; Polytaridis, Nicholas; Pupa, Philip Thomas; Reihman, Eli; Rindfleisch, Ashley Anne; Schunk, Sofie Wells; Simpson, Peter C.; Smith, Daniel; Vanslyke, Stephen J.; Vogel, Matthew T.; Walker, Tomas C.; West, Benjamin Elrod; Wiley, Atiim Joseph, System and method for providing alerts optimized for a user.
Davis, Anna Leigh; Garcia, Arturo; Hall, Thomas; Hampapuram, Hari; Hannemann, Christopher Robert; Harley-Trochimczyk, Anna Claire; Heintzman, Nathaniel David; Jackson, Andrea J.; Jepson, Lauren Hruby; Kamath, Apurv Ullas; Koehler, Katherine Yerre; Belliveau, Scott M.; Mandapaka, Aditya Sagar; Marsh, Samuel Jere; Morris, Gary A.; Pai, Subrai Girish; Pal, Andrew Attila; Polytaridis, Nicholas; Pupa, Philip Thomas; Reihman, Eli; Rindfleisch, Ashley Anne; Schunk, Sofie Wells; Bhavaraju, Naresh C.; Simpson, Peter C.; Smith, Daniel; Vanslyke, Stephen J.; Vogel, Matthew T.; Walker, Tomas C.; West, Benjamin Elrod; Wiley, Atiim Joseph; Bowman, Leif N.; Castillo, Rita M.; Constantin, Alexandra Elena; Draeger, Rian; Dunn, Laura J.; Gable, Gary Brian, System and method for providing alerts optimized for a user.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.